Figure 4.
Phase 2 trial of mini–hyper-CVD plus InO, with or without blinatumomab, in older patients with newly diagnosed Ph- negative B-cell acute lymphoblastic leukemia. Baseline patient's characteristic, CR duration, and OS. Reproduced from Jen et al34 with permission.

Phase 2 trial of mini–hyper-CVD plus InO, with or without blinatumomab, in older patients with newly diagnosed Ph- negative B-cell acute lymphoblastic leukemia. Baseline patient's characteristic, CR duration, and OS. Reproduced from Jen et al34 with permission.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal